Logo-jrip
ePublished: 01 Sep 2013
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2013;2(3): 109-111.
doi: 10.12861/jrip.2013.35
PMID: 25340144
PMCID: PMC4206025
  Abstract View: 1186
  PDF Download: 772

Letter to Editor

Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial

Ali Ghorbani 1 * , Farzad Jasemi-Zergani 1

1 Department of Nephrology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
*Corresponding Author: Ali Ghorbani, Department of Nephrology, Dialysis and Kidney Transplantation Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. dralighorbani@yahoo.com

Abstract

Implication for health policy/practice/research/medical education:Primary arteriovenous fistula (AVF), failure remains a major problem for hemodialysis patients. Vascular access thrombosis prophylaxis needs to start early in the end-stage renal disease patient. Ticlopidine seems to be effective and safe for prevention of primary AVF failure in hemodialysis patients.
Keywords: Arteriovenous fistula, Ticlopidine, Hemodialysis
Please cite this paper as: Ghorbani A, Jasemi-Zergani F. Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. J Ren Inj Prev 2013; 2(3): 109-111.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 1186

Your browser does not support the canvas element.


PDF Download: 772

Your browser does not support the canvas element.